Remove Antibody Remove Drugs Remove Genotoxicity Remove Protein
article thumbnail

IN FOCUS: Solvias

Pharmaceutical Technology

Our comprehensive analytical testing portfolio integrates a broad range of capabilities spanning all stages of drug discovery, development and manufacturing. Solvias is well equipped to provide stability testing for all stages of drug development. Integrated analytical services for pharmaceuticals. Quality control release testing.

article thumbnail

Treatment of Metastatic Triple-Negative Breast Cancer

The Pharma Data

SG is a first-in-class therapy targeting Trop-2, a protein frequently expressed in multiple types of epithelial tumors, such as TNBC, where high expression is associated with poor survival and relapse. Premedicate with a 2- or 3-drug combination regimen (e.g., More information about ASCENT is available at [link].

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Trodelvy®, the First Treatment for Metastatic Triple-Negative Breast Cancer Shown to Improve Progression-Free Survival and Overall Survival

The Pharma Data

Food and Drug Administration (FDA) has granted full approval to Trodelvy ® (sacituzumab govitecan-hziy) for adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (TNBC) who have received two or more prior systemic therapies, at least one of them for metastatic disease. DRUG INTERACTIONS.

HR 52
article thumbnail

Trodelvy® for the Treatment of Metastatic Urothelial Cancer

The Pharma Data

The FDA’s accelerated approval mechanism enables drugs that treat serious diseases with unmet medical need to be approved based on a surrogate or intermediate clinical endpoint. Premedicate with a two or three drug combination regimen (e.g., TRODELVY contains a genotoxic component, SN-38, and targets rapidly dividing cells.